Please assess the completion status of the following clinical trial:

Trial Title: Oxycodone/Naloxone Prolonged Release (OXN PR) Compared to Placebo to Demonstrate Improvement in Symptoms of Restless Legs Syndrome (RLS) in Subjects With Moderate to Severe Idiopathic RLS With Daytime Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Moderate to severe idiopathic RLS with daytime symptoms~Exclusion Criteria:~* Females who are pregnant or lactating.~* Subjects with evidence of significant structural abnormalities of the gastrointestinal tract.~* Subjects with evidence of impaired liver/kidney function upon entry into the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OXN PR (Type: EXPERIMENTAL): Different daily doses; intake every 12 hours
- PLA (Type: PLACEBO_COMPARATOR): Different daily doses; intake every 12 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).